Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study

 

IFN β-1b group

N = 303

Other DMTs group

N = 21

Total

N = 324

Age (years)

 

 Mean

41.5 ± 11.29

44.9 ± 11.15

41.8 ± 11.30

 Median (min–max)

40.0 (19.0–68.0)

43.0 (24.0–68.0)

40.0 (19.0–68.0)

Women, n (%)

207 (68.3)

14 (66.7)

221 (68.2)

Subtype of MS, n (%)

 CIS

7 (2.3)

0 (0.0)

7 (2.2)

 RRMS

286 (94.4)

19 (90.5)

305 (94.1)

 SPMS

10 (3.3)

2 (9.5)

12 (3.7)

MS disease history

 Duration since MS diagnosis (years)

  Mean

6.7 ± 6.36

9.5 ± 9.16

6.9 ± 6.59

  Median (min–max)

4.6 (0.2–35.0)

7.5 (0.3–43.4)

4.8 (0.2–43.4)

Presence of exacerbations, n (%)

120 (39.6)

13 (61.9)

133 (41.0)

 Number of exacerbations

  Mean

1.5 ± 0.74

1.9 ± 1.14

1.6 ± 0.79

  Median (min–max)

1.0 (0.0–5.0)

2.0 (1.0–5.0)

1.0 (0.0–5.0)

Reasons for switching to ExtaviPro™, n (%)

 Clinical reasonsa

   

  Availability of new auto-injector (patient already treated with Extavia®)

296 (97.7)

2 (9.5)

298 (92.0)

 Lack/loss of effectiveness of current treatment, as evidenced by

   

  returning/worsening/progressing MS symptoms

2 (0.7)

6 (28.6)

8 (2.5)

  Increasing frequency of relapses/symptomatic phases

2 (0.7)

3 (14.3)

5 (1.5)

  MRI evaluation

3 (1.0)

6 (28.6)

9 (2.8)

  Other

5 (1.7)

1 (4.8)

6 (1.9)

  Poor tolerance

9 (3.0)

7 (33.3)

16 (4.9)

Patient-centred reasons

 Compliance problem

19 (6.3)

9 (42.9)

28 (8.6)

 Patient unable to consistently store current therapy under special conditions

5 (1.7)

2 (9.5)

7 (2.2)

  1. Data are presented as mean ± SD, unless stated otherwise
  2. aMultiresponse option
  3. CIS clinically isolated syndrome, DMT disease-modifying treatment, IFN interferon, max maximum, min minimum, MRI magnetic resonance imaging, MS multiple sclerosis, RRMS relapsing-remitting multiple sclerosis, SD standard deviation, SPMS secondary progressive multiple sclerosis